{"prompt": "['Carbomer and Carboxymethylcellulose', '209510', 'Clinical Protocol V1.0', '12.2.1', 'Definition of Analysis Populations', 'The Safety population will comprise all randomized subjects who receive at least one dose', 'of the study product. This population will be based on the product the subject actually', 'received.', 'The Modified Intent-To-Treat (Treated or Exposed) population (MITT) will comprise all', 'randomized subjects who receive at least one dose of study product and have at least one', 'post randomization measure of gum comfort recorded via the questionnaire. This', 'population will be based on the study product to which the subject was randomized. Any', 'subject who receives a randomization number will be considered to have been', 'randomized.', 'The per protocol (PP) population includes all MITT subjects who fully comply with all', 'study procedures and restrictions. Deviations will be determined and applied prior to', 'unblinding and consist of variations in criteria likely to affect the interpretation of the', 'efficacy parameters.', '12.2.2', 'Exclusion of Data from Analysis', 'Exclusion of any data from the analyses will be determined during a Blind Data Review', 'Meeting prior to database lock. Any reasons for exclusion from an analysis population will be', 'listed, if applicable.', '12.2.3', 'Demographic and Baseline Characteristics', 'Age and other continuous variables will be summarized using descriptive statistics such as', 'means, medians and standard deviation. Gender, race and other categorical variables will be', 'summarized using frequency counts and percentages for the safety and MITT populations.', '12.2.4 Study Drug/Product Compliance', 'Compliance to the study product use will be tabulated and summarized for the safety and MITT', 'populations.', '12.2.4.1 Prior and Concomitant Medications', 'Prior medications, concomitant medications and significant non-drug therapies taken during', 'treatment will be listed for the safety population.', '12.2.5', 'Primary Analysis', 'The primary endpoint is the change from baseline in the mean overall gum comfort', 'questionnaire after 12 weeks of study. The subjects mean change from baseline for the Gum', 'Comfort Questionnaire will be compared between groups using analysis of covariance', '(ANCOVA) and test between treatment groups at the 5% level of significance. The model will', 'include the baseline value as covariate. Frequency distributions of the responses by treatment', 'group will be provided to detail the whole range of responses. Within and between group', \"estimates of treatment effects will be provided with 95% confidence intervals (CI's). The\", 'direction of the effect is anticipated in the direction of an improved gum comfort OHrQoL in', 'favour of the experimental denture adhesive over the no adhesive group.', 'In the case of the assumptions underlying the model not being supported, a suitable', 'transformation or non-parametric procedure will be used.', 'No imputation for missing values will be used.', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 50 of 65']['Carbomer and Carboxymethylcellulose', '209510', 'Clinical Protocol V1.0', 'The MITT population will be considered primary for this analysis. Analysis of the PP', 'population (if applicable) will be secondary.', '12.2.6', 'Secondary Analyses', 'Analysis of the same primary variable at 1, 4 and 8 weeks will be identical to that of the primary', 'variable at 12 weeks.', 'Other Questionnaire data at each time of assessment, the OHIP-Edent and GOHAI (including', 'any subscales of each) will be analyzed in a similar fashion to the primary variable.', 'A summary of the Product Sensory Questionnaire at 28 days will be provided for the adhesive', 'wearing group.', 'A summary of the incidence of denture bearing tissue assessments at each time of assessment', 'on a scale of 1-4 will be presented.', 'No correction to the testing level amongst the secondary variables will be made as these are', 'considered non definitive and hypothesis generating.', 'Further details will be given in the Reporting and Analysis Plan which will be finalized prior to', 'database lock.', '12.2.7', 'Safety Analysis', 'All AEs will be coded using MedDRA. AEs will be categorised as oral and non-oral by the', 'Clinical Research Director/ Scientist or designee prior to database lock. Treatment-emergent', 'adverse event (Oral AEs as well as all AEs) will be associated with the most recent treatment', 'received. The number of AEs and number of subjects with AEs will be listed and tabulated by', 'treatment. The results of OST exams will be tabulated. Incidents will be listed. The safety', 'analysis will be performed on the safety population.', '12.2.8', 'Handling of Dropouts and Missing Data', 'Missing data will not be replaced or imputed. Dropouts will be included in analyses up to the', 'last assessments at the point of discontinuation.', '12.2.9', 'Interim Analysis', 'No interim analysis is planned for this study', '13', 'STUDY GOVERNANCE CONSIDERATIONS', '13.1', 'Quality Control', 'In accordance with applicable regulations including GCP, and GSK CH procedures, GSK CH', 'or designee (i.e. third-party vendor) monitors will contact the site prior to the start of the study', 'to review with the site staff the protocol, study requirements, and their responsibilities to satisfy', 'regulatory, ethical, and GSK CH requirements.', 'When reviewing data collection procedures, the discussion will include identification,', 'agreement and documentation of data items for which the CRF will serve as the source', 'document.', 'GSK CH or designee will monitor the study and site activity to verify that the:', 'Data are authentic, accurate, and complete.', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 51 of 65']\n\n###\n\n", "completion": "END"}